PLRZ
Polyrizon Ltd.
Healthcare — Biotechnology
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nasal allergies blocker; and PL-16 for influenza blockers. Polyrizon Ltd. was incorporated in 2005 is headquartered in Ra'anana, Israel.
None
$10.51
+$0.42 (+4.25%)
Price History
52-Week Range
Sign in to add PLRZ to a watchlist or set price alerts.
Fundamentals
| Market Cap | $26.42M |
| P/E Ratio (TTM) | - |
| Forward P/E | - |
| EPS (TTM) | $-4.90 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -25.38% |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 60.3 |
| Beta | - |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $18.20 |
| 52-Week Low | $2.88 |
| 50-Day Avg | $13.95 |
| 200-Day Avg | $11.06 |
| Avg Volume | 44.6K |
| Volume | 16.3K |
Performance Analysis
NEUTRALPLRZ presents a mixed picture with both positive and negative indicators.
~
Trading at 50% of its 52-week range.
+
RSI at 60.3 shows positive momentum.
-
Price is below both the 50-day and 200-day moving averages — in a downtrend.
~
Wall Street consensus is "none".
Recent News
Loading news...
Last updated: Jul 02, 2026 13:26 UTC
Back to Screener Export Report